A leap of faith…

Who are the real hero’s in the discoveries of cancer treatment?  The brave patients who decide they want to be part of the clinical trials world; that’s who.

It’s hard enough being a part of cancer world, but to add the layer of clinical trials to that existence means earning a real medal of bravery.  Some patients sign on for Phase ONE trials.  Those are the real risk takers.  First line warriors willing to say “Bring it on, no matter what happens.”  That’s a patient who is on the first line of a new treatment, willing to give it all.

But all patients who sign up for trials are taking a leap of faith that this latest discovery is the one that will change the course of cancer treatment for so many, maybe this will be THE one that is that cancer silver bullet.

The researchers can’t live without these brave patients and neither can the oncologists.  They work as a team.  They move the science forward and even with the trial failures, they still move forward, learning from what didn’t work.

I am in awe of you; all of you who don’t hesitate for a second to say “Sign me up.”

It’s a leap of Olympic proportions.

VN:F [1.9.17_1161]
Rating: 5.0/5 (2 votes cast)
A leap of faith..., 5.0 out of 5 based on 2 ratings 1 Comment

{ 1 comment… read it below or add one }


Nan Holmes April 8, 2017 at 8:39 pm

There is really no way to thank all those brave souls who stepped up, even though the future was very uncertain. And real progress is being made thanks to the trials.


Leave a Comment

You can use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Johns Hopkins Medicine does not necessarily endorse, nor does Johns Hopkins Medicine edit or control, the content of posted comments by third parties on this website. However, Johns Hopkins Medicine reserves the right to remove any such postings that come to the attention of Johns Hopkins Medicine which are deemed to contain objectionable or inappropriate content. Read our Commenting Disclaimer.

Previous post:

Next post: